Oncotarget on the forefront of breast cancer research

While spreading awareness for breast cancer is of utmost importance, it’s even more crucial to be aware of the life-saving research taking place to treat and one day eradicate this disease that effects so many of us personally. Oncotarget researchers are some of those working tirelessly towards this goal. Listen to an audio podcast of Oncotarget on Itunes.

In November 2017 Eureka Alert reported that Oncotarget researchers discovered a potential treatment for a particularly aggressive type that effects approximately 15% of breast cancer patients known as triple negative breast cancer (TNBC). The prognosis for this disease has been particularly grim due to the lack of hormone receptors on the malignant cells which prevents the hormone-based treatments used in other strains of breast cancer from being effective, allowing the disease to spread. Researchers at Oncotarget have found in preliminary testing that by grafting estrogen receptors to the effected cells, they are able to slow and even regress the disease by allowing it to be more susceptible to treatment. While this method is still in very early stages of research, the potential could be ground breaking for the people effected by this type of breast cancer. Check Oncotarget journal at scimagojr.com

Oncotarget also recently awarded 4 researchers from around the world grants at Frontiers in Cancer Reseasrch 2017. Their research ranges from renal cancer to mesothelioma. “The Frontiers in Cancer Science meeting brings together top cancer experts from around the globe and as travel sponsor, Oncotarget is proud to have provided the opportunity for new and groundbreaking research from four international institutions to be shared at the meeting,” Oncotarget’s editor-in-chief, Mikhail Blagosklonny, stated.

Follow: https://twitter.com/oncotargetjrnl?lang=en

To keep up with some of the latest in cancer news and research, please visit Oncotarget’s Journal.

Leave a Comment

Your email address will not be published.